Introduction
ANGPTL3 and ANGPTL4, primarily produced by the liver, are angiopoietin-like proteins that play a crucial role in regulating triglyceride metabolism. They achieve this by inhibiting the breakdown of triglyceride-rich lipoproteins. Experimental evidence demonstrates that Angptl3 and Angptl4 differentially inhibit Lipoprotein lipase (LPL) to regulate circulating triglyceride levels during various nutritional states, such as feeding and fasting. ANGPTL3's molecular structure resembles angiopoietins, which are vascular endothelial growth factors. Studies using deletion mutants of human Angiopoietin 5 have shown that the N-terminal domain (amino acids 17-207), rather than the C-terminal fibrinogen-like domain (amino acids 207-460), is responsible for increasing plasma triglyceride levels in mice.
Description
Recombinant Human ANGPTL3, produced in HEK cells, is a single, glycosylated polypeptide chain encompassing amino acids 17-460. With a total of 450 amino acids, it has a calculated molecular mass of 52.6 kDa. The protein is fused to a 6-amino acid His tag at the C-terminus and purified using proprietary chromatographic techniques.
Physical Appearance
White, lyophilized powder after filtration.
Formulation
The product is filtered through a 0.4 μm filter and lyophilized from a solution of 0.5 mg/ml in 0.05 M phosphate buffer (pH 7.4) containing 0.075 M NaCl.
Solubility
To reconstitute, add deionized water to achieve a working concentration of 0.5 mg/ml and allow the lyophilized pellet to dissolve completely. Note: This product is not sterile. Filter it through an appropriate sterile filter before use in cell culture.
Stability
Store the lyophilized protein at -20°C. After reconstitution, aliquot the product to minimize freeze-thaw cycles. Reconstituted protein can be stored at 4°C for a limited period.
Purity
Purity is determined to be greater than 95.0% using SDS-PAGE analysis.
Synonyms
Angiopoietin 5, ANGPT5, ANGPTL3, Angiopoietin Like Protein 3.
Amino Acid Sequence
SRIDQDNSSF DSLSPEPKSR FAMLDDVKIL ANGLLQLGHG LKDFVHKTKG QINDIFQKLN IFDQSFYDLS LQTSEIKEEE KELRRTTYKL QVKNEEVKNM SLELNSKLES LLEEKILLQQ KVKYLEEQLT NLIQNQPETP EHPEVTSLKT FVEKQDNSIK DLLQTVEDQY KQLNQQHSQI KEIENQLRRT SIQEPTEISL SSKPRAPRTT PFLQLNEIRN VKHDGIPAEC TTIYNRGEHT SGMYAIRPSN SQVFHVYCDV ISGSPWTLIQ HRIDGSQNFN ETWENYKYGF GRLDGEFWLG LEKIYSIVKQ SNYVLRIELE DWKDNKHYIE YSFYLGNHET NYTLHLVAIT GNVPNAIPEN KDLVFSTWDH KAKGHFNCPE GYSGGWWWHD ECGENNLNGK YNKPRAKSKP ERRRGLSWKS QNGRLYSIKS TKMLIHPTDS ESFEHHHHHH.